GoAI
Get started
Innoviva, Inc. logo

Innoviva, Inc.

INVA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$21.07

+$0.07 · +0.33%

Aug 21, 4:00 PM ET

INVA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

100

Deep Value

Momentum

48

Neutral

Sentiment

80

Bullish

Risk resilience

76

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Pavel Raifeld
Listed since
Oct 5, 2004
Employees
159

Market position

Day range

Current $21.07

52-week range

Current $21.07

Open
$20.885
Previous close
$21.00
Volume
499.38K
0.64× average
Average volume
774.28K
Average daily volume
Market cap
1.56B USD
Beta
0.34
Market reference 1
50-day average
$21.809
-3.39% below average
200-day average
$21.7679
-3.21% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.07B USD
P/E (TTM)
4.33×
P/B (TTM)
1.25×
P/S (TTM)
3.51×
EV / EBITDA
2.78×
Earnings yield
20.13%
Free cash flow yield
13.84%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
73.09%
Operating margin
36.66%
Net margin
80.56%
Return on equity
23.12%
Return on assets
16.58%
Return on invested capital
8.57%

Financial health

Debt / equity
0.22×
Current ratio
14.64×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends109%72%35%-3%Gross margin, FY2021: 100.00%Gross margin, FY2022: 95.84%Gross margin, FY2023: 86.27%Gross margin, FY2024: 89.80%Gross margin, FY2025: 72.33%Operating margin, FY2021: 95.72%Operating margin, FY2022: 62.47%Operating margin, FY2023: 36.68%Operating margin, FY2024: 46.52%Operating margin, FY2025: 38.52%Net margin, FY2021: 67.84%Net margin, FY2022: 64.56%Net margin, FY2023: 57.89%Net margin, FY2024: 6.52%Net margin, FY2025: 63.78%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 95.84%. Gross margin FY2023 86.27%. Gross margin FY2024 89.80%. Gross margin FY2025 72.33%. Operating margin FY2021 95.72%. Operating margin FY2022 62.47%. Operating margin FY2023 36.68%. Operating margin FY2024 46.52%. Operating margin FY2025 38.52%. Net margin FY2021 67.84%. Net margin FY2022 64.56%. Net margin FY2023 57.89%. Net margin FY2024 6.52%. Net margin FY2025 63.78%.

Income trends

Revenue

425.13M USD+18.52%

Operating income

163.75M USD-1.87%

Net income

271.17M USD+1059.22%
Income trends across reported periods465.3M USD304.61M USD143.91M USD−16.78M USDRevenue, FY2021: 391.87M USDRevenue, FY2022: 331.34M USDRevenue, FY2023: 310.46M USDRevenue, FY2024: 358.71M USDRevenue, FY2025: 425.13M USDOperating income, FY2021: 375.1M USDOperating income, FY2022: 207M USDOperating income, FY2023: 113.89M USDOperating income, FY2024: 166.87M USDOperating income, FY2025: 163.75M USDNet income, FY2021: 265.85M USDNet income, FY2022: 213.92M USDNet income, FY2023: 179.72M USDNet income, FY2024: 23.39M USDNet income, FY2025: 271.17M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 391.87M USD. Revenue FY2022 331.34M USD. Revenue FY2023 310.46M USD. Revenue FY2024 358.71M USD. Revenue FY2025 425.13M USD. Operating income FY2021 375.1M USD. Operating income FY2022 207M USD. Operating income FY2023 113.89M USD. Operating income FY2024 166.87M USD. Operating income FY2025 163.75M USD. Net income FY2021 265.85M USD. Net income FY2022 213.92M USD. Net income FY2023 179.72M USD. Net income FY2024 23.39M USD. Net income FY2025 271.17M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue425.13M USD358.71M USD310.46M USD331.34M USD391.87M USD
Cost of goods sold117.61M USD36.6M USD42.64M USD13.79M USD—
Gross profit307.52M USD322.11M USD267.82M USD317.55M USD391.87M USD
Research and development30.6M USD13.65M USD33.92M USD41.43M USD576K USD
Selling, general, and administrative113.17M USD115.69M USD98.23M USD63.54M USD16.19M USD
Operating expenses143.77M USD155.25M USD153.94M USD110.55M USD16.76M USD
Interest income21.09M USD19.14M USD15.82M USD6.37M USD1.84M USD
Interest expense16.7M USD22.21M USD19.16M USD15.79M USD19.07M USD
Depreciation and amortization40.23M USD25.9M USD21.78M USD5.58M USD13.83M USD
Operating income163.75M USD166.87M USD113.89M USD207M USD375.1M USD
Net income271.17M USD23.39M USD179.72M USD213.92M USD265.85M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+82.90%
11 comparable reports
Latest EPS result
1.14
Estimate 0.44 · Beat by 161.47%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.071.460.840.22Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 0.26, estimate 0.34, surprise -23.53%, Miss. Q2 2025, reported May 7, 2025: actual 0.74, estimate 0.294, surprise +151.87%, Beat. Q3 2025, reported Aug 6, 2025: actual 0.77, estimate 0.57, surprise +35.09%, Beat. Q4 2025, reported Nov 5, 2025: actual 1.08, estimate 0.46, surprise +134.78%, Beat. Q1 2026, reported Feb 25, 2026: actual 1.94, estimate 0.34, surprise +470.59%, Beat. Q2 2026, reported May 6, 2026: actual 0.44, estimate 0.43, surprise +2.33%, Beat. Q3 2026, reported Aug 5, 2026: actual 1.14, estimate 0.436, surprise +161.47%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 0.5, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates124.37M108.88M93.39M77.89MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 91.81M USD, estimate 86.8M USD, surprise +5.77%, Beat. Q2 2025, reported May 7, 2025: actual 88.63M USD, estimate 82.67M USD, surprise +7.21%, Beat. Q3 2025, reported Aug 6, 2025: actual 100.28M USD, estimate 92.04M USD, surprise +8.96%, Beat. Q4 2025, reported Nov 5, 2025: actual 107.8M USD, estimate 91.36M USD, surprise +17.99%, Beat. Q1 2026, reported Feb 25, 2026: actual 114.61M USD, estimate 102.62M USD, surprise +11.68%, Beat. Q2 2026, reported May 6, 2026: actual 97.99M USD, estimate 101.57M USD, surprise -3.52%, Miss. Q3 2026, reported Aug 5, 2026: actual 119.59M USD, estimate 110.98M USD, surprise +7.75%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 115.4M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$38.00

80.35% upside
Past 12 months12-month forecastHigh $42.00Average $38.00Low $34.00

INVA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding INVA

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
89.48M
Weight
0.08%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
46.8M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
40.44M
Weight
0.05%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
33.84M
Weight
0.02%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Value ETF logoVanguard Morningstar Small-Cap Value ETFVBR
Market value
21.47M
Weight
0.03%
AUM
68.3B USD
Expense ratio
0.05%
Price / 1D
$249.18+0.68%
Avantis U.S. Small Cap Value ETF logoAvantis U.S. Small Cap Value ETFAVUV
Market value
17.79M
Weight
0.06%
AUM
31.27B USD
Expense ratio
0.25%
Price / 1D
$126.45+0.66%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
16.96M
Weight
0.02%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
14.9M
Weight
0.10%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%

Continue in GoAI

Research INVA

research.disclaimer